Patent ID: 11896634
Assignee: BAYLOR COLLEGE OF MEDICINE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The method according to claim 1, wherein the CAR comprises an antigen binding domain comprising:
a VL comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:16 and a VH comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:17, and further wherein the VL comprises LC-CDR1: SEQ ID NO:10; LC-CDR2: SEQ ID NO:11; and LC-CDR3: SEQ ID NO:12; and the VH comprises HC-CDR1: SEQ ID NO:13; HC-CDR2: SEQ ID NO:14; and HC-CDR3: SEQ ID NO:15;, or
a VL comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:24 and a VH comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:25, and further wherein the VL comprises LC-CDR1: SEQ ID NO:18; LC-CDR2: SEQ ID NO:19; and LC-CDR3: SEQ ID NO:20; and the VH comprises HC-CDR1: SEQ ID NO:21; HC-CDR2: SEQ ID NO:22; and HC-CDR3: SEQ ID NO:23;, or
a VL comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:32 and a VH comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:33, and further wherein the VL comprises LC-CDR1: SEQ ID NO:26; LC-CDR2: SEQ ID NO:27; and LC-CDR3: SEQ ID NO:28; and the VH comprises HC-CDR1: SEQ ID NO:29; HC-CDR2: SEQ ID NO:30; and HC-CDR3: SEQ ID NO:31;, or
a VL comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:63 and a VH comprising, or consisting of, an amino acid sequence having at least 75% sequence identity to SEQ ID NO:64, and further wherein the VL comprises LC-CDR: SEQ ID NO:57; LC-CDR2: SEQ ID NO:58; and LC-CDR3: SEQ ID NO:59; and the VH comprises HC-CDR1: SEQ ID NO:60; HC-CDR2: SEQ ID NO:61; and HC-CDR3: SEQ ID NO:62.